IN2014MN01759A - - Google Patents
Info
- Publication number
- IN2014MN01759A IN2014MN01759A IN1759MUN2014A IN2014MN01759A IN 2014MN01759 A IN2014MN01759 A IN 2014MN01759A IN 1759MUN2014 A IN1759MUN2014 A IN 1759MUN2014A IN 2014MN01759 A IN2014MN01759 A IN 2014MN01759A
- Authority
- IN
- India
- Prior art keywords
- protein
- relates
- renal
- syndecan
- sparc
- Prior art date
Links
- 206010061481 Renal injury Diseases 0.000 abstract 3
- 108010012820 Follistatin-Related Proteins Proteins 0.000 abstract 1
- 102000019203 Follistatin-Related Proteins Human genes 0.000 abstract 1
- 102100036683 Growth arrest-specific protein 1 Human genes 0.000 abstract 1
- 101710135446 Growth arrest-specific protein 1 Proteins 0.000 abstract 1
- 102100030301 MHC class I polypeptide-related sequence A Human genes 0.000 abstract 1
- 101710102605 MHC class I polypeptide-related sequence A Proteins 0.000 abstract 1
- 102100035721 Syndecan-1 Human genes 0.000 abstract 1
- 108090000058 Syndecan-1 Proteins 0.000 abstract 1
- 102100022205 Tumor necrosis factor receptor superfamily member 21 Human genes 0.000 abstract 1
- 101710187751 Tumor necrosis factor receptor superfamily member 21 Proteins 0.000 abstract 1
- 238000003556 assay Methods 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 239000000104 diagnostic biomarker Substances 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 208000037806 kidney injury Diseases 0.000 abstract 1
- 239000003550 marker Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 238000012544 monitoring process Methods 0.000 abstract 1
- 238000004393 prognosis Methods 0.000 abstract 1
- 239000000092 prognostic biomarker Substances 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 230000019491 signal transduction Effects 0.000 abstract 1
- 238000011269 treatment regimen Methods 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
- A61M1/16—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis with membranes
- A61M1/1601—Control or regulation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/04—Liquids
- A61M2202/0413—Blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/75—General characteristics of the apparatus with filters
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/34—Genitourinary disorders
- G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/56—Staging of a disease; Further complications associated with the disease
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicinal Chemistry (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Anesthesiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
Abstract
The present invention relates to methods and compositions for monitoring diagnosis prognosis and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular the invention relates to using a one or more assays configured to detect a kidney injury marker selected from the group consisting of SPARC Follistatin related protein 1 Tumor necrosis factor receptor superfamily member 21 Growth arrest specific protein 1 MHC class I polypeptide related sequence A Syndecan 1 and WNTl inducible signaling pathway protein 1 as diagnostic and prognostic biomarkers in renal injuries.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261603912P | 2012-02-27 | 2012-02-27 | |
| US201261603906P | 2012-02-27 | 2012-02-27 | |
| PCT/US2013/028000 WO2013130591A1 (en) | 2012-02-27 | 2013-02-27 | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014MN01759A true IN2014MN01759A (en) | 2015-07-03 |
Family
ID=49083233
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN1759MUN2014 IN2014MN01759A (en) | 2012-02-27 | 2013-02-27 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20150010929A1 (en) |
| EP (1) | EP2820146A4 (en) |
| JP (1) | JP2015508181A (en) |
| CN (1) | CN104379758A (en) |
| AU (1) | AU2013226181A1 (en) |
| CA (1) | CA2865559A1 (en) |
| HK (1) | HK1204339A1 (en) |
| IN (1) | IN2014MN01759A (en) |
| WO (1) | WO2013130591A1 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140363834A1 (en) * | 2012-01-28 | 2014-12-11 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| WO2016123163A2 (en) | 2015-01-27 | 2016-08-04 | Kardiatonos, Inc. | Biomarkers of vascular disease |
| HK1248808A1 (en) * | 2015-06-11 | 2018-10-19 | 阿斯图特医药公司 | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003219275B2 (en) * | 2002-03-07 | 2008-01-24 | Cambridge Enterprise Ltd | SCD fingerprints |
| US20050130193A1 (en) * | 2003-09-10 | 2005-06-16 | Luxon Bruce A. | Methods for detecting, diagnosing and treating human renal cell carcinoma |
| FR2872579B1 (en) * | 2004-06-30 | 2006-11-24 | Pasteur Institut | DETECTION OF TUBERCULOSIS AND MYCOBACTERIUM TUBERCULOSIS INFECTION USING HBHA |
| US20090178145A1 (en) * | 2005-05-11 | 2009-07-09 | The Procter & Gamble Company | Methods and targets for identifying compounds for regulating angiogenesis |
| US7623910B2 (en) * | 2006-03-10 | 2009-11-24 | University Of Rochester | ECG-based differentiation of LQT1 and LQT2 mutation |
| CN106370857A (en) * | 2008-10-21 | 2017-02-01 | 阿斯图特医药公司 | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| EP2394166B1 (en) * | 2009-02-06 | 2016-07-13 | Astute Medical, Inc. | Methods for diagnosis and prognosis of renal injury and failure |
| US20120183543A1 (en) * | 2009-05-08 | 2012-07-19 | Novartis Ag | Diagnostic biomarkers for fibrotic disorders |
| WO2013096740A1 (en) * | 2011-12-21 | 2013-06-27 | Alere San Diego Inc. | Methods and compositions for assigning likelihood of chronic kidney disease progression |
-
2013
- 2013-02-27 CN CN201380020012.4A patent/CN104379758A/en active Pending
- 2013-02-27 CA CA2865559A patent/CA2865559A1/en not_active Abandoned
- 2013-02-27 US US14/381,532 patent/US20150010929A1/en not_active Abandoned
- 2013-02-27 AU AU2013226181A patent/AU2013226181A1/en not_active Abandoned
- 2013-02-27 WO PCT/US2013/028000 patent/WO2013130591A1/en not_active Ceased
- 2013-02-27 HK HK15104711.3A patent/HK1204339A1/en unknown
- 2013-02-27 EP EP13755796.3A patent/EP2820146A4/en not_active Withdrawn
- 2013-02-27 IN IN1759MUN2014 patent/IN2014MN01759A/en unknown
- 2013-02-27 JP JP2014558960A patent/JP2015508181A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2013226181A1 (en) | 2014-09-18 |
| WO2013130591A1 (en) | 2013-09-06 |
| CA2865559A1 (en) | 2013-09-06 |
| JP2015508181A (en) | 2015-03-16 |
| EP2820146A4 (en) | 2015-12-16 |
| EP2820146A1 (en) | 2015-01-07 |
| US20150010929A1 (en) | 2015-01-08 |
| HK1204339A1 (en) | 2015-11-13 |
| CN104379758A (en) | 2015-02-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3070474A3 (en) | Methods and compositions for diagnosis and prognosis of renal injury and renal failure | |
| IN2014MN00377A (en) | ||
| MX2011008323A (en) | Methods and compositions for diagnosis and prognosis of renal injury and renal failure. | |
| MX2011002233A (en) | Methods and compositions for diagnosis and prognosis of renal injury and renal failure. | |
| MX388231B (en) | METHODS AND COMPOSITIONS FOR THE DIAGNOSIS AND PROGNOSIS OF KIDNEY INJURY AND KIDNEY FAILURE. | |
| MX2014000283A (en) | Methods and compositions for diagnosis and prognosis of renal injury and renal failure. | |
| EP2585826A4 (en) | Methods and compositions for diagnosis and prognosis of renal injury and renal failure | |
| CY1117784T1 (en) | METHODS AND RECOMMENDATIONS FOR DIAGNOSIS AND PREDICTION OF DYNAMIC DAMAGE AND DYNAMIC DEFICIENCY | |
| EA201792497A1 (en) | ANTIBODIES TO GITR FOR DIAGNOSIS OF MALIGNANT TUMOR | |
| WO2011119934A3 (en) | Methods and materials for detecting colorectal neoplasm | |
| MX2012001559A (en) | Methods and compositions for diagnosis and prognosis of renal injury and renal failure. | |
| NZ630277A (en) | Methods and compositions for diagnosis and prognosis of renal injury and renal failure | |
| PH12013500544A1 (en) | Breast cancer diagnostics | |
| NZ608316A (en) | Methods and compositions for diagnosis and prognosis of renal injury and renal failure | |
| BR112013021056A2 (en) | monoclonal antibody, hybridoma cell line, diagnostic kit, methods for producing a monoclonal antibody and binding agent, purified amino acid sequence binding agent, method for obtaining a coding nucleic acid sequence, antibody molecule encoding isolated nucleic acid, vector, isolated host cell, fusion protein, screening method for the presence of a disease, a condition, methods of diagnosing an individual, prognosis for an individual, and monitoring an individual, and , method for detecting the presence or absence of cervical cancer | |
| ATE554389T1 (en) | APEX AS A MARKER FOR LUNG CANCER | |
| WO2013138044A8 (en) | Methods and materials for noninvasive detection of colorectal neoplasia associated with inflammatory bowel disease | |
| MX2019008260A (en) | Methods and compositions for evaluation and treatment of renal injury and renal failure based on c-c motif chemokine ligand 14 measurement. | |
| WO2015077382A3 (en) | Combined cytology and molecular testing for early detection of esophageal adenocarcinoma | |
| MX339765B (en) | Methods and compositions for diagnosis and prognosis of renal injury and renal failure. | |
| BR112015021507A2 (en) | methods and compositions for the diagnosis of preeclampsia | |
| WO2015023503A3 (en) | Compositions and methods for multimodal analysis of cmet nucleic acids | |
| MX2012003168A (en) | Methods and composition for diagnosis and prognosis of renal injury and renal failure. | |
| ATE468535T1 (en) | USE OF NNMT AS A MARKER FOR LUNG CANCER | |
| IN2014MN00949A (en) |